- Home
- LDWY vs INTS Comparison
LDWY vs INTS Comparison
Compare LDWY & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- INTS
- Stock Information
- Founded
- LDWY 1990
- INTS 2012
- Country
- LDWY United States
- INTS United States
- Employees
- LDWY N/A
- INTS N/A
- Industry
- LDWY Advertising
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- INTS Health Care
- Exchange
- LDWY Nasdaq
- INTS Nasdaq
- Market Cap
- LDWY 9.2M
- INTS 9.4M
- IPO Year
- LDWY 1991
- INTS 2023
- Fundamental
- Price
- LDWY $4.90
- INTS $0.32
- Analyst Decision
- LDWY
- INTS Strong Buy
- Analyst Count
- LDWY 0
- INTS 3
- Target Price
- LDWY N/A
- INTS $8.50
- AVG Volume (30 Days)
- LDWY 6.5K
- INTS 2.7M
- Earning Date
- LDWY 08-18-2025
- INTS 08-07-2025
- Dividend Yield
- LDWY N/A
- INTS N/A
- EPS Growth
- LDWY N/A
- INTS N/A
- EPS
- LDWY N/A
- INTS N/A
- Revenue
- LDWY $42,183,000.00
- INTS N/A
- Revenue This Year
- LDWY N/A
- INTS N/A
- Revenue Next Year
- LDWY N/A
- INTS N/A
- P/E Ratio
- LDWY N/A
- INTS N/A
- Revenue Growth
- LDWY 425.12
- INTS N/A
- 52 Week Low
- LDWY $3.02
- INTS $0.26
- 52 Week High
- LDWY $5.53
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- LDWY 50.82
- INTS 37.08
- Support Level
- LDWY $4.85
- INTS $0.28
- Resistance Level
- LDWY $5.12
- INTS $0.32
- Average True Range (ATR)
- LDWY 0.16
- INTS 0.06
- MACD
- LDWY -0.05
- INTS 0.01
- Stochastic Oscillator
- LDWY 7.84
- INTS 7.43
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.